Dietary Supplementation with Omega-3 Polyunsaturated Fatty Acids Reduces Opioid-Seeking Behaviors and Alters the Gut Microbiome.
Analgesics, Opioid
Animals
Behavior, Animal
/ drug effects
Brain
/ drug effects
Dietary Supplements
Disease Models, Animal
Drug-Seeking Behavior
/ drug effects
Fatty Acids, Omega-3
/ administration & dosage
Gastrointestinal Microbiome
/ drug effects
Male
Mice, Inbred C57BL
Microglia
/ drug effects
Opioid-Related Disorders
/ drug therapy
Oxycodone
Recurrence
Substance Withdrawal Syndrome
/ drug therapy
DHA
EPA
Intravenous self-administration
anxiety
mice
microbiome-brain axis
opioid
polyunsaturated fatty acids
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
14 Aug 2019
14 Aug 2019
Historique:
received:
19
07
2019
revised:
07
08
2019
accepted:
12
08
2019
entrez:
17
8
2019
pubmed:
17
8
2019
medline:
6
2
2020
Statut:
epublish
Résumé
Opioids are highly addictive substances with a relapse rate of over 90%. While preclinical models of chronic opioid exposure exist for studying opioid dependence, none recapitulate the relapses observed in human opioid addiction. The mechanisms associated with opioid dependence, the accompanying withdrawal symptoms, and the relapses that are often observed months or years after opioid dependence are poorly understood. Therefore, we developed a novel model of chronic opioid exposure whereby the level of administration is self-directed with periods of behavior acquisition, maintenance, and then extinction alternating with reinstatement. This profile arguably mirrors that seen in humans, with initial opioid use followed by alternating periods of abstinence and relapse. Recent evidence suggests that dietary interventions that reduce inflammation, including omega-3 polyunsaturated fatty acids (n-3 PUFAs), may reduce substance misuse liability. Using the self-directed intake model, we characterize the observed profile of opioid use and demonstrate that an n-3-PUFA-enriched diet ameliorates oxycodone-seeking behaviors in the absence of drug availability and reduces anxiety. Guided by the major role gut microbiota have on brain function, neuropathology, and anxiety, we profile the microbiome composition and the effects of chronic opioid exposure and n-3 PUFA supplementation. We demonstrate that the withdrawal of opioids led to a significant depletion in specific microbiota genera, whereas n-3 PUFA supplementation increased microbial richness, phylogenetic diversity, and evenness. Lastly, we examined the activation state of microglia in the striatum and found that n-3 PUFA supplementation reduced the basal activation state of microglia. These preclinical data suggest that a diet enriched in n-3 PUFAs could be used as a treatment to alleviate anxiety induced opioid-seeking behavior and relapse in human opioid addiction.
Identifiants
pubmed: 31416242
pii: nu11081900
doi: 10.3390/nu11081900
pmc: PMC6723154
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Fatty Acids, Omega-3
0
Oxycodone
CD35PMG570
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDA NIH HHS
ID : DA00010
Pays : United States
Organisme : CSRD VA
ID : IK2 CX001717
Pays : United States
Organisme : Health Services Research and Development
ID : VA CDAII IK2CX001717
Organisme : Shirley and Stefan Hatos Foundation
ID : NA
Organisme : NIDA NIH HHS
ID : P50 DA005010
Pays : United States
Références
Brain Res Brain Res Rev. 2000 Aug;33(1):13-33
pubmed: 10967352
Am J Psychiatry. 2002 Oct;159(10):1642-52
pubmed: 12359667
Eur J Pharmacol. 2003 Feb 28;463(1-3):55-65
pubmed: 12600702
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5
pubmed: 12883005
J Physiol. 2004 Jul 1;558(Pt 1):263-75
pubmed: 15133062
Nat Neurosci. 2005 Nov;8(11):1442-4
pubmed: 16251985
J Clin Psychiatry. 2007 Jul;68(7):1056-61
pubmed: 17685742
Lipids Health Dis. 2007 Sep 18;6:21
pubmed: 17877810
Neuropsychopharmacology. 2009 Mar;34(4):912-22
pubmed: 18784649
Trends Cogn Sci. 2009 Sep;13(9):372-80
pubmed: 19716751
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
J Clin Psychiatry. 2011 Aug;72(8):1054-62
pubmed: 20584525
Neuroscience. 2010 Nov 10;170(4):1179-88
pubmed: 20696216
Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):3047-52
pubmed: 21282636
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16050-5
pubmed: 21876150
Trends Neurosci. 2011 Nov;34(11):599-609
pubmed: 21963090
Commun Integr Biol. 2011 Jul;4(4):492-4
pubmed: 21966581
Neurogastroenterol Motil. 2011 Dec;23(12):1132-9
pubmed: 21988661
Mol Psychiatry. 2013 Jun;18(6):666-73
pubmed: 22688187
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Trends Neurosci. 2013 May;36(5):305-12
pubmed: 23384445
Physiol Behav. 2013 Jun 13;118:171-7
pubmed: 23672853
Biochim Biophys Acta. 2013 Nov;1828(11):2553-63
pubmed: 23792066
Behav Brain Res. 2013 Nov 1;256:279-83
pubmed: 23968589
Mamm Genome. 2014 Feb;25(1-2):49-74
pubmed: 24281320
Curr Protoc Immunol. 2014 Nov 03;107:7.41.1-11
pubmed: 25367129
Genome Biol. 2014;15(12):550
pubmed: 25516281
Psychoneuroendocrinology. 2015 Aug;58:79-90
pubmed: 25965872
Aging Clin Exp Res. 2016 Feb;28(1):165-6
pubmed: 26025463
J Lipid Res. 2015 Aug;56(8):1511-8
pubmed: 26063461
Curr Protoc Mouse Biol. 2015 Dec 02;5(4):291-309
pubmed: 26629773
Am J Clin Nutr. 2016 Feb;103(2):330-40
pubmed: 26718417
Biochem Pharmacol. 2016 Jun 15;110-111:1-15
pubmed: 26827942
eNeuro. 2016 Feb 02;3(1):null
pubmed: 26866057
ACS Chem Biol. 2016 Jul 15;11(7):1795-9
pubmed: 27128111
Nat Neurosci. 2016 Aug;19(8):995-8
pubmed: 27294511
Brain Behav Immun. 2017 Jan;59:21-37
pubmed: 27423492
J Clin Med. 2016 Jul 27;5(8):null
pubmed: 27472373
F1000Res. 2016 Jul 19;5:null
pubmed: 27508068
Brain Behav Immun. 2017 Jan;59:38-48
pubmed: 27621225
Trends Pharmacol Sci. 2016 Nov;37(11):963-976
pubmed: 27670390
Nat Commun. 2016 Oct 19;7:13123
pubmed: 27759003
Microbiol Spectr. 2016 Nov;4(6):
pubmed: 27837747
PLoS One. 2017 Apr 5;12(4):e0175090
pubmed: 28380057
Int J Psychiatry Med. 2017 Mar;52(2):196-201
pubmed: 28792293
Sci Rep. 2017 Sep 11;7(1):11079
pubmed: 28894110
Biochem Soc Trans. 2017 Oct 15;45(5):1105-1115
pubmed: 28900017
PLoS One. 2017 Oct 3;12(10):e0185796
pubmed: 28973019
Int J Mol Sci. 2017 Dec 07;18(12):null
pubmed: 29215589
Front Psychiatry. 2018 Apr 23;9:119
pubmed: 29740351
Neuron. 2018 Jun 6;98(5):886-903
pubmed: 29879391
Schizophr Res. 2019 Feb;204:295-303
pubmed: 30241990
Neuropsychopharmacology. 2018 Dec;43(13):2606-2614
pubmed: 30258112
JAMA Psychiatry. 2019 Feb 1;76(2):208-216
pubmed: 30516809
Nat Rev Neurosci. 2019 Jan;20(1):5-18
pubmed: 30518959
Nutr Neurosci. 2019 Feb 22;:1-10
pubmed: 30794085
Sci Rep. 2019 Mar 1;9(1):3281
pubmed: 30824791
J Clin Invest. 2019 Mar 26;129(6):2480-2484
pubmed: 30913040
Biochem Biophys Res Commun. 1996 Jul 25;224(3):855-62
pubmed: 8713135
J Neurochem. 1996 Aug;67(2):822-9
pubmed: 8764612
Int J Vitam Nutr Res. 1997;67(4):272-8
pubmed: 9285258
Drug Metab Dispos. 1998 May;26(5):383-7
pubmed: 9571218